Verdant PhytoMed — Products & Services

Verdant PhytoMed’s product portfolio has been designed to address the full spectrum of pharmaceutical-grade medicinal cannabis demand across international markets. All products are manufactured in compliance with EU-GMP standards and undergo rigorous quality testing including High Performance Liquid Chromatography (HPLC), microbial screening,…

Verdant PhytoMed (Pty) Ltd Business PlanSection 4 › Products & Services

Section 4 · Business Plan

Products & Services

Verdant PhytoMed’s product portfolio has been designed to address the full spectrum of pharmaceutical-grade medicinal cannabis demand across international markets. All products are manufactured in compliance with EU-GMP standards and undergo rigorous quality testing including High Performance Liquid Chromatography (HPLC), microbial screening,…

4.1 Product Portfolio

Verdant PhytoMed’s product portfolio has been designed to address the full spectrum of pharmaceutical-grade medicinal cannabis demand across international markets. All products are manufactured in compliance with EU-GMP standards and undergo rigorous quality testing including High Performance Liquid Chromatography (HPLC), microbial screening, heavy metal analysis, pesticide residue testing, and terpene profiling.

Product Line 1: Dried Medicinal Cannabis Flower (EU-GMP Grade)

Pharmaceutical-grade dried cannabis flower, cultivated under GACP conditions and processed in GMP-certified facilities. Available in standardised THC-dominant, CBD-dominant, and balanced chemotype strains. Target markets include German pharmacies (Apotheken), UK specialist clinics, and Australian Therapeutic Goods Administration (TGA)-approved distributors.

Estimated Selling Price: ZAR 45–75 per gram (FOB
Cape Town), depending on cannabinoid profile and strain
Year 3 Revenue Contribution: Approximately 55% of
total revenue

Product Line 2: Cannabis Extracts & Oils

Full-spectrum and broad-spectrum cannabis extracts, CBD isolate, and standardised oil formulations. These products target pharmaceutical manufacturers, compounding pharmacies, and nutraceutical companies seeking bulk active pharmaceutical ingredients (APIs).

Estimated Selling Price: ZAR 200–450 per gram of
extract (concentration-dependent)
Year 3 Revenue Contribution: Approximately 35% of
total revenue

Product Line 3: Pharmaceutical Bulk Inputs & Research Supply

Bulk cannabis biomass and standardised cannabinoid reference materials supplied to pharmaceutical R&D departments, university research programmes, and contract research organisations (CROs). This revenue stream builds long-term strategic relationships and positions the Company as a preferred supplier in the scientific community.

Year 3 Revenue Contribution: Approximately 10% of
total revenue

4.2 Quality Assurance Framework

The Company’s quality management system (“QMS”) is designed to meet or exceed the following international standards:

  • EU-GMP (European Medicines Agency guidelines for medicinal cannabis)

  • GACP (WHO Good Agricultural and Collection Practices)

  • ISO 17025 (laboratory testing and calibration)

  • HACCP (Hazard Analysis and Critical Control Points for food-grade processing)

  • Full seed-to-sale traceability via integrated ERP and track-and-trace software

This document contains proprietary and confidential information. Distribution without written consent is prohibited.